United Nations office on drug and Crime (UNODC). World Drug Report 2020: Drug use and health consequences. Vienna: United Nations publication, Sales No. E.20.XI.6; 2020.
Collins C. Adverse health effects of marijuana use. N Engl J Med. 2014;371(9):879.
Hoch E, Bonnetn U, Thomasius R, Ganzer F, Havemann-Reinecke U, Preuss UW. Risks associated with the non-medicinal use of cannabis. Dtsch Arztebl Int. 2015 Apr;112(16):271–8.
Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One. 2013;8(10):e76635.
Hosseini S, Oremus M. The effect of age of initiation of Cannabis use on psychosis, depression, and anxiety among youth under 25 years. Can J Psychiatr. 2019 May;64(5):304–12.
Kurth AE, Cherutich P, Conover R, Chhun N, Bruce RD, Lambdin BH. The opioid epidemic in Africa and its impact. Curr Addict Rep. 2018;5(4):428–53.
National Authority for the Campaign Againist Alcohol and Drug Abuse (NACADA). National Survey on Alcohol and Drug Abuse Among Secondary School; 2016. p. 1–6.
National Authority for the campaign Againist alcohol and drug abuse (NACADA). Rapid situation assessment of drugs and substance abuse in Kenya. NACADA Rep. 2017;1(1):1–119 Available from: http://nacada.go.ke/?page_id=387#.
Kiburi SK, Molebatsi K, Obondo A, Kuria MW. Adverse childhood experiences among patients with substance use disorders at a referral psychiatric hospital in Kenya. BMC Psychiatry. 2018;18(1):1–12.
Razzaghi EM. A warm welcome to the diagnostic and statistical manual of mental disorders, fifth edition? Iran J Psychiatry Behav Sci. 2014;8:1–4.
Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207–25. https://doi.org/10.1080/10550887.2012.694598.
Larney S, Peacock A, Leung J, Colledge S. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: A systematic review; 2017.
Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. eries Drug Use 1 Global patterns of opioid use and dependence : harms to populations, interventions , and future action. Lancet. 2019;394(10208):1560–79. https://doi.org/10.1016/S0140-6736(19)32229-9.
Ayanga D, Shorter D, Kosten TR. Update on pharmacotherapy for treatment of opioid use disorder. Expert Opin Pharmacother. 2016;17(17):2307–18. https://doi.org/10.1080/14656566.2016.1244529.
McBrien H, Luo C, Sanger N, Zielinski L, Bhatt M, Zhu XM, et al. Cannabis use during methadone maintenance treatment for opioid use disorder: a systematic review and meta-analysis. CMAJ Open. 2019. https://doi.org/10.9778/cmajo.20190026.
Lake S, St. Pierre M. The relationship between cannabis use and patient outcomes in medication-based treatment of opioid use disorder: a systematic review. Clin Psychol Rev. 2020;82:101939. https://doi.org/10.1016/j.cpr.2020.101939.
Franklyn AM, Eibl JK, Gauthier GJ, Marsh DC. The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada. PLoS One. 2017;12(11):1–11.
Zielinski L, Bhatt M, Sanger N, Plater C, Worster A, Varenbut M, et al. Association between cannabis use and methadone maintenance treatment outcomes: an investigation into sex differences. Biol Sex Differ. 2017;8(1):1–10.
Bawor M, Dennis BB, Varenbut M, Daiter J, Marsh DC, Plater C, et al. Sex differences in substance use, health, and social functioning among opioid users receiving methadone treatment: a multicenter cohort study. Biol Sex Differ. 2015;6(1):1–11. https://doi.org/10.1186/s13293-015-0038-6.
Morgan N, Daniels W, Subramaney U. A prospective observational study of heroin users in Johannesburg , South Africa : Assessing psychiatric comorbidities and treatment outcomes. Compr Psychiatry. 2019;95:152137. https://doi.org/10.1016/j.comppsych.2019.152137.
Kidorf M, Disney ER, King VL, Neufeld K, Beilenson PL, Brooner RK. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend. 2004;74:115–22.
Teoh J, Fei B, Yee A, Hussain M, Habil B. Psychiatric comorbidity among patients on methadone maintenance therapy and its influence on quality of life. Am J Addict. 2016;25:49–55.
Epstein DH, Preston KL, Epstein DH. Does Cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? A review of past findings, and more evidence against. Addictions. 1993;98(3):269–79.
Shams I, Sanger N, Bhatt M, Rosic T, Luo C, Shahid H, et al. The association between health conditions and cannabis use in patients with opioid use disorder receiving methadone maintenance treatment. BJPsych Open. 2019;5(6):1–8.
Bagra I, Krishnan V, Rao R, Agrawal A. Does Cannabis use influence opioid outcomes and quality of life among buprenorphine maintained patients? A cross-sectional, Comparative Study. J Addict Med. 2018;12(4):315–20.
Scavone JL, Sterling RC, Weinstein SP, Van Bockstaele EJ. Impact of cannabis use during stabilization on methadone maintenance treatment. Am J Addict. 2013;22(4):344–51.
Kral AH, Wenger L, Novak SP, Chu D, Corsi KF, Coffa D, et al. Is cannabis use associated with less opioid use among people who inject drugs? Drug Alcohol Depend. 2015;153:236–41. https://doi.org/10.1016/j.drugalcdep.2015.05.014.
Socías ME, Wood E, Lake S, Nolan S, Fairbairn N, Hayashi K, et al. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis. Addiction. 2018;113(12):2250–8.
Wiese B, Wilson-Poe AR. Emerging evidence for cannabis’ role in opioid use disorder. Cannabis Cannabinoid Res. 2018;3(1):179–89.
Suzuki J, Weiss RD. Cannabinoids for the treatment of opioid use disorder: where is the evidence? J Addict Med. 2021;15(2):91–2.
Scheibe A, Marks M, Shelly S, Gerardy T, Domingo AK, Hugo J. Developing an advocacy agenda for increasing access to opioid substitution therapy as part of comprehensive services for people who use drugs in South Africa. S Afr Med J. 2018;108(10):800–2.
International Harm Reduction. Global State of Harm Reduction: 2019 updates. Harm Reduct Int. 2019:1–63 Available from: https://www.hri.global/global-state-of-harm-reduction-2019.
Lambdin BH, Masao F, Chang O, Kaduri P, Mbwambo J, Magimba A, et al. Methadone treatment for HIV prevention- feasibility, retention, and predictors of attrition in Dar Es Salaam, Tanzania: a retrospective cohort study. Clin Infect Dis. 2014;59(5):735–42.
Ubuguyu M, Tran OC, Bruce RD, Masao F, Nyandindi C, Sabuni N, et al. Improvements in health-related quality of life among methadone maintenance clients in Dar Es Salaam, Tanzania. Int J Drug Policy. 2016;30:74–81. https://doi.org/10.1016/j.drugpo.2016.03.005.
Guise A, Ndimbii J, Igonya EK, Owiti F, Strathdee SA, Rhodes T. Integrated and differentiated methadone and HIV care for people who use drugs: a qualitative study in Kenya with implications for implementation science. Health Policy Plan. 2019;34(2):110–9.
Rhodes T, Guise A, Ndimbii J, Strathdee S, Ngugi E, Platt L, et al. Is the promise of methadone Kenya’s solution to managing HIV and addiction? A mixed-method mathematical modelling and qualitative study. BMJ Open. 2015;5(3):e007198.
Khalili P, Nadimi AE, Baradaran HR, Janani L, Rahimi-Movaghar A, Rajabi Z, et al. Validity of self-reported substance use: research setting versus primary health care setting. Subst Abus Treat Prev Policy. 2021;16(1):1–13.
White WL, Campbell MD, Spencer RD, Hoffman HA, Crissman B, DuPont RL. Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention. J Psychoactive Drugs. 2014;46(2):114–22. https://doi.org/10.1080/02791072.2014.901587.
Hoch E, Preuss W, Ferri M. Digital interventions for problematic Cannabis users in non-clinical Settings : findings from a systematic review and Meta-analysis. Dtsch Arztebl Int. 2015;112:271–8. https://doi.org/10.3238/arztebl.2015.0271.
Le Foll B, Sabioni P. Psychosocial and pharmacological interventions for the treatment of cannabis use disorder. F1000Research. 2018;7(0):1–8.
Heikman PK, Muhonen LH, Ojanperä IA. Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine. BMC Psychiatry. 2017;17(1):1–11.
Carlsen SL, Lunde L. Opioid and Polydrug use among patients in opioid maintenance treatment. Subst Abus Rehabil. 2020;11:9–18.
Morgan N, Daniels W, Subramaney U. An inverse relationship between alcohol and heroin use in heroin users post Detoxi fi cation. Subst Abus Rehabil. 2020;11:1–8.
Epstein AJ, Barry CL, Fiellin DA, Busch SH. Patient valuation of different approaches to mental health and substance use disorder treatment. Value Health. 2015;18(3):A277.
Mayet A, Lions C, Roux P, Mora M, Maradan G, Morel A, et al. Variations in Cannabis use level and correlates in opiate-users on methadone maintenance treatment: a French prospective study. J Subst Abus Treat. 2015;58:100–5. https://doi.org/10.1016/j.jsat.2015.06.015.
Horwood LJ, Fergusson DM, Hayatbakhsh MR, Najman JM, Coffey C, Patton GC, et al. Cannabis use and educational achievement: findings from three Australasian cohort studies. Drug Alcohol Depend. 2010;110(3):247–53. https://doi.org/10.1016/j.drugalcdep.2010.03.008.
Thompson K, Leadbeater B, Ames M, Merrin GJ. Associations between marijuana use trajectories and educational and occupational success in young adulthood. Prev Sci. 2019;20(2):257–69.
Moradinazar M, Farnia V, Alikhani M, Karyani AK, Rezaei S, Rezaeian S, et al. Factors related to relapse in patients with substance-related disorders under methadone maintenance therapy: decision tree enalysis. Oman Med J. 2020;35(1):e89.